Roche Holding stock

RO · SIX · CHF

Secondary listing. The primary listing is Roche Holding · SIX (CHF)

CHF 414.20Change from previous close: +0.53%Absolute change: +CHF 2.20

Close · November 16, 2026

Price history

+38.07% over the period

1 year: from CHF 300.00 (November 17, 2025) to CHF 414.20 (November 16, 2026), +38.07%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026CHF 414.20
October 30, 2026CHF 411.20
September 30, 2026CHF 360.80
August 31, 2026CHF 360.40
July 31, 2026CHF 358.60
June 30, 2026CHF 339.20
May 29, 2026CHF 336.60
April 30, 2026CHF 326.60
March 31, 2026CHF 327.20
February 27, 2026CHF 381.40
January 30, 2026CHF 356.00
December 30, 2025CHF 335.20
November 28, 2025CHF 319.40
November 17, 2025CHF 300.00

At a glance

  • The company

    Develop pharmaceuticals and diagnostics for diseases including cancer, infectious diseases, and respiratory disorders

  • Latest results

    Quarter to September 30, 2026

TickerLandia's take on Roche Holding

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk lowCHF 297.20
52-wk highCHF 417.80

−0.86% from the 52-week high

Analysts · 3 analysts

Average targetCHF 470.00+13.47% vs. price

Buy 1 · Hold 2 · Sell 0 · Buy

TickerLandia Fingerprint: Roche Holding

Compared with similar companies: very low growth.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Roche Holding is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Roche Holding's P/E today is 25.8, above the median of its last 10 fiscal years (21.1; between 18.3 and 26.2 from 2016 to 2025). Roche Holding's P/E (trailing 12 months): 26.9, +25% against the median of a group of 10 similar companies (21.5).

P/E compared with its history

Compared with 10 similar companies

Roche Holding's metrics compared with similar companies
MetricRoche HoldingPosition in the groupBand
P/E (trailing 12 months)26.9High
Forward P/E18.7High
Operating margin33.1%Middle
ROE38.1%High
Debt/equity0.91Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Roche Holding. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

CHF 31.45B

Latest quarter · Q2 2026

Net income

CHF 6.87B

Latest quarter · Q2 2026

Quarterly net margin

21.8%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
CHF 328.27B
P/E
26.9
EPS
CHF 15.33
Volume
19.04K
Daily trading
€12.12M
Dividend yield
2.61%
Last ex-dividend on March 12, 2026

How Roche Holding is changing

All results
  • Revenue grew 1.0% a year on average over the last 5 years

  • Operating margin rose from 31.3% to 33.1%

  • Profits turn into cash: free cash flow equal to 121% of net income

Returns

Roche Holding returns with dividends

CHF 1,000 invested in Roche Holding 5 years ago, on November 16, 2021, would be worth CHF 1,220 today with dividends reinvested: +21.96% in total, +4.05% per year. On price alone it would be CHF 1,041 (+4.12%).

PeriodRoche HoldingSMICHF 1,000 becomes
1 month+7.70%+8.46%CHF 1,077
6 months+24.83%+14.27%CHF 1,248
Year to date+23.57%+13.86%CHF 1,236
1 year+42.62%+19.91%CHF 1,426
3 years+82.06%+41.93%CHF 1,821
5 years+21.96%+20.30%CHF 1,220
10 years+141.76%+90.88%CHF 2,418

Over the last 6 months it has done better than 38% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. SMI: price only. Calculate your investment

The chart in detail

Roche Holding: technical analysis

Roche Holding is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 4.3% below its all-time closing high (CHF 433.00, April 11, 2022).

Trend
Upward
RSI (14 sessions)
67
Between 30 and 70
vs 200-session average
+16.83%

Support and resistance

Price areas where Roche Holding has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last priceCHF 414.20
  3. SupportCHF 383.00−7.53%2 touches, last on August 26, 2026
  4. SupportCHF 378.50−8.62%4 touches, last on September 28, 2026
  5. SupportCHF 357.90−13.59%2 touches, last on August 14, 2026

Volatility and risk

Over the last year it has moved roughly in line with the SMI.

Beta (1 year) vs SMI
1.20
Volatility (60 sessions, annualised)
20.8%
Largest fall in the last year
−19.00%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Roche Holding: seasonality

Average monthly price change over 37 years

+1.3%Jan−0.9%Feb+0.1%Mar+1.7%Apr+1.9%May−0.2%Jun+2.2%Jul−0.6%Aug−0.8%Sep+1.6%Oct+1.6%Nov+0.8%Dec

Over the last 37 years, the strongest month for Roche Holding has been July: +2.21% on average, positive in 22 years out of 37. The weakest has been February: −0.93% on average, positive in 18 years out of 37. November, the current month, has been positive in 21 years out of 36 (+1.62% on average).

Show chart data
MonthAverageMedianPositive years
January+1.32%+1.28%23 of 36
February−0.93%−0.83%18 of 37
March+0.15%+1.22%20 of 37
April+1.66%0.00%18 of 37
May+1.94%+2.05%23 of 37
June−0.25%−0.96%15 of 37
July+2.21%+1.02%22 of 37
August−0.64%−0.45%14 of 37
September−0.81%−0.65%16 of 37
October+1.56%+2.11%24 of 37
November+1.62%+0.91%21 of 36
December+0.84%+0.25%18 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Roche Holding and its competitors

Based in Basel, Switzerland, Roche Holding AG was founded in 1896 and operates in pharmaceuticals and diagnostics. Its pharma portfolio covers therapeutic areas such as oncology, neurological disorders, ophthalmology, dermatology and transplantation. Its diagnostics business offers in vitro tests for diseases including cancer, diabetes and hepatitis, along with diagnostic instruments and digital health solutions. The group sells in Europe, North America, Latin America, Asia, Africa, Australia and New Zealand.

Headquarters
Basel, Switzerland
Employees
103,249
Roche Holding and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Roche HoldingRO$391.54B33.1%26.9+24.83%
NovartisNOVN$301.99B34.0%32.1+16.25%
AstraZenecaAZN$286.82B25.8%26.5+2.92%
Novo NordiskNOVO.B$181.48B50.8%10.9−3.84%
SanofiSAN$116.24B22.3%25.3+18.71%
GSKGSK$101.36B30.5%17.9+3.57%

Same industry or related industries, similar size. Compare Roche Holding with its competitors · Full profile